Abstract
The delivery of some classes of drugs is challenging. Solubility, absorption, distribution, and duration of action may all be altered by combination with vehicle molecules. It has already been discovered that polyethylene glycol – which is used as a stabiliser in peptide drug formulations – has biological activity in its own right, including potential neuroprotective properties. In this article we review the evidence for confounding activity for four distinct compounds that have been used as solvents and/or carrier molecules for the delivery of lipophilic drugs under investigation for potential neuroprotective properties. We discuss the evidence that cyclodextrins, ethanol, dimethyl sulphoxide, and a castor oil derivative - Cremophor™ EL – have all been found to have mild to moderate neuroprotective effects. We argue that this has probably reduced the statistical power and increased the Type II error rates of neuroprotection experiments that have employed these vehicles, and suggest experimental design considerations to help correct the problem. However, we also note that the properties of these compounds may represent an opportunity for drug development, particularly for the newer compounds that have been subject to only limited experimental investigation.
Keywords: Carrier, Cyclodextrin, DMSO, Ethanol, Cremophor, Lipophilic, Neuroprotection, Vehicle.
Current Neurovascular Research
Title:Vehicles for Lipophilic Drugs: Implications for Experimental Design, Neuroprotection, and Drug Discovery
Volume: 10 Issue: 4
Author(s): Jack Rivers-Auty and John C. Ashton
Affiliation:
Keywords: Carrier, Cyclodextrin, DMSO, Ethanol, Cremophor, Lipophilic, Neuroprotection, Vehicle.
Abstract: The delivery of some classes of drugs is challenging. Solubility, absorption, distribution, and duration of action may all be altered by combination with vehicle molecules. It has already been discovered that polyethylene glycol – which is used as a stabiliser in peptide drug formulations – has biological activity in its own right, including potential neuroprotective properties. In this article we review the evidence for confounding activity for four distinct compounds that have been used as solvents and/or carrier molecules for the delivery of lipophilic drugs under investigation for potential neuroprotective properties. We discuss the evidence that cyclodextrins, ethanol, dimethyl sulphoxide, and a castor oil derivative - Cremophor™ EL – have all been found to have mild to moderate neuroprotective effects. We argue that this has probably reduced the statistical power and increased the Type II error rates of neuroprotection experiments that have employed these vehicles, and suggest experimental design considerations to help correct the problem. However, we also note that the properties of these compounds may represent an opportunity for drug development, particularly for the newer compounds that have been subject to only limited experimental investigation.
Export Options
About this article
Cite this article as:
Rivers-Auty Jack and Ashton C. John, Vehicles for Lipophilic Drugs: Implications for Experimental Design, Neuroprotection, and Drug Discovery, Current Neurovascular Research 2013; 10 (4) . https://dx.doi.org/10.2174/15672026113109990021
DOI https://dx.doi.org/10.2174/15672026113109990021 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Recent Patents on Oxidative Stress-Related Biomarkers in Chronic Heart Failure: The Central Role of Endothelium and Myeloperoxidase
Recent Patents on Biomarkers Gene Therapy for the Prevention of Ischemia / Reperfusion Injury in Organ Transplantation
Current Gene Therapy Neutrophil-Derived Cytokines: Potential Therapeutic Targets in Inflammation
Current Drug Targets - Inflammation & Allergy Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Current Understanding of Inflammatory Responses in Acute Kidney Injury
Current Gene Therapy Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
Current Drug Targets Serpinins: Role in Granule Biogenesis, Inhibition of Cell Death and Cardiac Function
Current Medicinal Chemistry Progress Towards the Development of Anti-Inflammatory Inhibitors of IKKβ
Current Topics in Medicinal Chemistry TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17β-Estradiol Treatment
Current Neurovascular Research Potential for Discovery of Neuroprotective Factors in Serum and Tissue from Hibernating Species
Mini-Reviews in Medicinal Chemistry Extracellular Vesicles as Therapeutics for Brain Injury and Disease
Current Pharmaceutical Design Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System
CNS & Neurological Disorders - Drug Targets Liver Protective Effects of Extra Virgin Olive Oil: Interaction between Its Chemical Composition and the Cell-signaling Pathways Involved in Protection
Endocrine, Metabolic & Immune Disorders - Drug Targets Nitric Oxide Releasing Nanomaterials for Cancer Treatment: Current Status and Perspectives
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Current Vascular Pharmacology A Systematic Review of a Naturally Occurring Iridoid: Catalpol
Current Bioactive Compounds Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Current Pharmaceutical Design